Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353660 | 0.92 | VNN1 (0.41) | CYP2D6VNN1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL25469327 | 0.90 | CYP2D6 (0.47) | CYP2D6VNN1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL19159469 | 0.86 | CYP2C9 (0.41) | CYP2D6CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL27381021 | 0.85 | CYP2D6 (0.59) | CYP2D6CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL20962690 | 0.84 | CYP2D6 (0.44) | CYP2D6VNN1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL18347975 | 0.82 | CYP2C9 (0.45) | CYP2D6CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL16849114 | 0.82 | CYP2C9 (0.45) | CYP2D6CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL18390600 | 0.81 | USP2 (0.42) | CYP2D6VNN1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL18705154 | 0.79 | HRH3 (0.47) | CYP2D6CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL19909687 | 0.79 | CHRNB2 (0.36) | CYP2D6VNN1CYP3A4HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3133/4885VNN1 4773/4885CYP3A4 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.